DUBLIN--(BUSINESS WIRE)--The "Birch Pollen Allergy - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
"Birch Pollen Allergy - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Birch Pollen Allergy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Scope of the report
- The report provides a snapshot of the pipeline development for the Birch Pollen Allergy
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Birch Pollen Allergy
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Birch Pollen Allergy
- The report also covers the dormant and discontinued pipeline projects related to the Birch Pollen Allergy
Key Topics Covered:
1. Report Introduction
2. Birch Pollen Allergy Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
Appendix
Companies Mentioned
- ALK-Abello A/S
- Anergis SA
- Biomay AG
- Circassia Pharmaceuticals Plc
- HAL Allergy BV
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vc48b8/global_birch?w=4
